Generally, HDAC inhibitors are well tolerated at the doses required to inhibit tumor growth, and their toxicities in both humans and animals are distinct from those associated with conventional chemotherapeutic drugs [332,333]. The gene discussed is HDAC9; the disease is neoplasm.